Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.

Journal of the American College of Cardiology - 4 Jan 2005

Marín Francisco, González-Conejero Rocío, Lee Kaeng W, Corral Javier, Roldán Vanessa, López Francisca, Sogorb Francisco, Caturla Juan, Lip Gregory Y H, Vicente Vicente

Abstract excerpt

OBJECTIVES: The aim of this study was to evaluate the pharmacogenetic role of the factor XIII (FXIII) valine 34 leucine (Val34Leu) polymorphism in the fibrinolytic therapy of acute myocardial infarction (MI). BACKGROUND: Fibrinolytic therapy is an established treatment for acute MI, but up to 40% of treated patients do not achieve optimal tissue reperfusion. The FXIII Val34Leu polymorphism is one of the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Factor XIII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine

Share to Multivariate Analysis

Share to Myocardial Infarction

Share to Polymorphism, Genetic

Share to Risk Factors

Share to Valine

Source

Identifiers

PMID: 15629368
DOI: 10.1016/j.jacc.2004.09.051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.PMID 15629368Read ↗

Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis.Semantic proximity Read ↗

Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males.Semantic proximity Read ↗

Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction.Semantic proximity Read ↗

Effect of factor XIII-A Val34Leu polymorphism on myocardial infarction risk: a meta-analysis.Semantic proximity Read ↗

Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years.Semantic proximity Read ↗

Factor XIII val34leu and the risk of myocardial infarction.Semantic proximity Read ↗

Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A.Semantic proximity Read ↗

Coagulation factor XIII-A Val34Leu polymorphism and the risk of coronary artery disease and myocardial infarction in a Chinese Han population.Semantic proximity Read ↗

Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke.Semantic proximity Read ↗

FXIII-A Leu34 genetic variant in premature coronary artery disease: a genotype--phenotype case control study.Semantic proximity Read ↗

Factor XIII A subunit Val34Leu polymorphism in patients suffering atherothrombotic ischemic stroke.Semantic proximity Read ↗

The association between factor XIII Val34Leu polymorphism and early myocardial infarction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.